key: cord-1040938-s1h38832
authors: Sin, Jonathan H; Richards, I Ian; Ribisi, Maria S
title: Maintaining comprehensive pharmacy services during a pandemic: recommendations from a designated COVID-19 facility
date: 2020-06-13
journal: Am J Health Syst Pharm
DOI: 10.1093/ajhp/zxaa194
sha: 8e44cb1da7b6d1d8da4893a7d68fa5445c0eafbf
doc_id: 1040938
cord_uid: s1h38832

In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

In the event of a disaster, pharmacists are capable of undertaking crucial roles in hospitals and health systems, including various actions within the 4 phases of disaster management: prevention/mitigation, preparedness, response, and recovery. 1 Previous events have highlighted pharmacists' endeavors to fulfill needs of their patients, institutions, and communities as part of the disaster medicine response. [2] [3] [4] [5] [6] [7] The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID- 19) is no exception, and it was declared a pandemic by the World Health Organization in March 2020.

In addition to infectious risks and a lack of definitive treatment(s) or an approved vaccine, challenges include surges COVID-19 cases resulting in overwhelmed hospitals, healthcare staffing issues, and critical supply shortages including drugs. Medication management remains an important aspect of care for patients with COVID-19, including management of novel and experimental pharmacologic agents, pharmacotherapy to support life-sustaining and critical care treatments, and drugs needed to treat underlying comorbidities and for chronic disease management.

The University Hospital of Brooklyn at SUNY Downstate Health Sciences University, a tertiary care urban academic medical center in Brooklyn, NY, was declared a designated "COVID 19 only" treatment facility by the governor of New York State, the epicenter of the US outbreak.

The hospital leadership, department administrators, and frontline staff worked collaboratively in order to prepare for the influx of patients with COVID-19. The department of pharmacy was tasked with devising and implementing a sustainable action plan for continuity of pharmacy services. Herein, we provide recommendations on maintaining comprehensive pharmacy and medication management services during the COVID-19 pandemic.

Emergency preparedness and disaster management. The department of pharmacy should be routinely involved in emergency preparedness and disaster management on the institutional level. [8] [9] [10] This involvement may include conference calls with the hospital leadership, providers, and administrators of other departments to discuss the evolving COVID-19 situation and/or direct involvement with the hospital incident command system. It is crucial for the department of pharmacy to remain knowledgeable of hospital plans as they are being deliberated, including plans for bed management, opening of treatment areas, conversion of critical care units, and the disposition/transfer processs. This knowledge will provide advance notice to deploy resources timely and efficiently. Examples include modifying medication inventory in preexisting automated dispensing cabinets (ADCs) to match the needs of the patient population, redistributing or adding emergency supplies such as crash carts and intubation trays to more acute care units, and reallocating clinical services to accommodate areas of highest need.

During these communications, the department of pharmacy should have a venue to regularly report on specific changes or trends in medication usage during the COVID-19 pandemic, clinical guidelines, staffing plans, and updates on critical drug shortages and inventory management. As the circumstances unfold and develop, the department of pharmacy should concomitantly be creating plans for eventual recovery and plans to be implemented in the event of a potential resurgence, with delineation of action items and responsible personnel.

The specifics of these plans may be modified as a result of additional hospital plans, new clinical information, changes in resource allocation, and lessons learned.

Operational pharmacy services. A surge of patients with COVID-19 is expected to correlate with increased needs for operational pharmacy services. As such, medication dispensing functions must be maintained, and available automation resources should be a focus of optimization. For institutions with ADCs, more rapid turnover of supply and higher incidences of stock-outs can be expected; thus, it is prudent to monitor drug utilization and make real-time adjustments, such as modifying par levels and adding delivery/restocking runs when resources allow. Similarly, the high clinical acuity of some patients with COVID-19 may result in more rapid turnover of emergency supplies, including crash carts, airway/intubation trays, and other institution-specific boxes and kits. Turnover and usage can be tracked manually or with automated kit tracking solutions, if available. The department of pharmacy may need to assess the number of carts and kits that are deployed to patient care areas in conjunction with providers and adjust quantities accordingly. Additional pharmacist, pharmacy intern, and pharmacy technician resources may be required to ensure adequate restocking of depleted emergency equipment items, followed by accurate verification. For institutions that involve multiple departments in restocking crash carts (eg, pharmacy, materials management, and central sterile departments), it may be worth initiating a conversation to agree on the most efficient workflow during the COVID-19 pandemic.

Another operational area expected to be impacted is sterile compounding. For institutions that are increasing bed capacity for critically ill and step-down patients with COVID-19, the need for compounded sterile preparations (CSPs) such as continuous-infusion and piggyback medications will likely grow. Inpatients with documented or suspected COVID-19 pneumonia may potentially be instructed to take nothing by mouth for a variety of clinical reasons, further increasing the demand for CSPs. Depending on the sterile compounding workflow and available resources and technology, increasing the batching frequency for nonpatient-specific doses of CSPs may be an option to minimize wastage and improve operational efficiency. 11, 12 Candidates to consider include commonly used critical care medications (eg, vasopressors, sedatives, neuromuscular blocking agents) and antiinfective drugs. Under normal conditions, operational pharmacy personnel are often present on patient care units and nursing stations to deliver, restock, and retrieve medications and medicationrelated equipment. In order to minimize potential exposures and movement throughout patient care areas, institutions with pneumatic tube delivery systems can capitalize on the system to decrease the number of physical deliveries by sending supply either directly to nursing stations or to the nearest inpatient satellite pharmacy, if applicable; acquisition of additional empty carriers may be considered, depending on the system's maximum capacity.

Staff required to visit patient care or isolation areas should be provided with adequate PPE 6 according to the expected level of exposure and institution-specific guidelines. For medications and medication trays returned from COVID-19 isolation areas, a separate secure location for quarantining of those items for an appropriate period of time before recirculation back into active inventory can be identified. Crash carts returned to the department of pharmacy should be cleaned with approved disinfectants. It may be prudent to agree upon an accepted disinfecting process with individuals who handle and transport crash carts (eg, nursing, security, transport team personnel) and to determine where carts should be located to minimize contamination of carts and their contents, including detailed discussion of cart storage in patient care areas and specific cart placement during an active resuscitation. Resourcewise, it may not be possible for every medical team or service to have dedicated clinical pharmacy coverage; this highlights the importance of collaboratively discussing which targeted services (eg, antimicrobial stewardship, medication profile review, review of high-risk medications, therapeutic drug monitoring) can be feasibly delivered. An additional approach could be to leverage "pharmacy acuity" (medication regimen complexity) scoring tools to prioritize patient care needs, if the institution's electronic medical record (EMR) and/or clinical decision support software possess those capabilities. 18 This process of multidisciplinary evaluation, discussion, and decision-making is of extreme importance to maintain and promote safe and cost-conscious medication usage. 20 Drug shortage management. As the demand for experimental COVID-19 treatments and medications necessary to support life-sustaining therapies skyrockets, drug supply chains will become strained. 21 This disruption may include suppliers, manufacturers, and wholesale distributors. Drug shortages add further layers of complexity to medication management during a public health crisis. 22 Critical drugs that have already been impacted include opioids, sedatives, vasopressors, neuromuscular blocking agents, respiratory agents and inhalers, and numerous antiinfectives; experimental COVID-19-targeted agents have also been impacted. On an institutional level, the department of pharmacy should collaborate with the pharmacy and therapeutics committee, providers, clinical content experts, and other stakeholders to disseminate timely drug shortage communications. For example, use of oral opioids and adjunct sedative-analgesic agents can be promoted to potentially minimize the need for intravenous rescue therapy. Intermittent bolus dosing of opioids, sedatives, and neuromuscular blocking agents can be considered in preference to continuous infusion drips as a conservation strategy, if clinically appropriate. Guidelines for critical drug shortage recommendations may include approved restrictions and/or alternative pharmacotherapy options, if applicable. 23 Inventory and supply chain managers should remain in constant contact with wholesale distributors to determine product availability, product allocation, and the status of incoming shipments. The department of pharmacy may also consider contacting manufacturers to obtain personalized availability reports and to directly place emergency purchase orders. Keeping a running vendor list with names of representatives and contact information for internal use may prove to be beneficial when additional drug shortages arise or in the event of a resurgence of COVID-19 cases. Another approach is to collaborate with state and local healthcare organizations and advocacy groups to contact the Federal Emergency Management Agency's state coordinating officers to request immediate release of available quantities of critical medications from the Strategic National Stockpile to a state's department of health. While seeking additional procurement options, the supply chain team and/or other designated individuals should be tasked with keeping accurate inventory counts of critical medications on at least a daily basis. In doing so they should remain cognizant of any closed patient care or procedural areas, as well as any specialty services with a significantly reduced census, as those areas and services may have supplies of necessary drugs that can be centralized and subsequently redistributed to higher-need areas.

the care of patients with COVID-19, pharmacists with expertise in clinical informatics can play a substantial role in emergency preparedness by applying their knowledge of pharmacy practice, medication safety, health information technology, and clinical information systems. 24 Immediate actions involve customized maintenance of the EMR to align with clinician needs.

Custom ordering templates and order sets may be built to simplify medication selection for providers caring for patients with COVID-19. For knowledge delivery, computerized prescriber order entry and clinical decision support systems can be modified to proactively and interactively highlight drug shortages, current restrictions, and appropriate alternatives.

During disaster-related drug shortages, the department of pharmacy may receive medications from a new manufacturer, new dosage forms or volumes, or alternative pharmacologic agents. If the institution utilizes barcode-assisted and/or knowledge-based medication administration technology, pharmacy informaticists should ensure that the technology will recognize previously unencountered National Drug Code numbers so that it continues to enable accurate and safe medication administration. 25 In the setting of lack of evidence from randomized controlled trials, hospitals and health systems may wish to gather and analyze institution-specific data to validate current COVID-19 protocols, identify areas of further investigation, or determine if changes in treatment are warranted. Pharmacy informaticists, pharmacists, and pharmacy residents can be part of a multidisciplinary research team or task force to assist with generating usage reports, data collection, data analysis, presentation of results and recommendations for internal process improvement, and potential submission of abstracts or manuscripts to contribute to the medical literature. If the hospital or health system is participating in randomized trials of experimental therapies for COVID-19, pharmacy informaticists may need to collaborate with investigators to develop an efficient process for randomization notification, investigational drug ordering, and documentation.

When implementing workflow changes and modifying existing processes, the department of pharmacy should make an effort to analyze data to trend activities for continuous process improvement. The departmental leadership may modify dashboards or "scorecards" to integrate information specific to disaster management during the COVID-19 pandemic. Information generated from activities such as emergency response and code cart exchanges, order verification, sterile compounding, drug procurement, ADC turnover and stockouts, medication regimen complexity scoring, clinical interventions, and safety incidents will be valuable in optimizing staffing and reallocating operational or clinical resources if necessary. 26, 27 Functionalities of the EMR and business analytics can be leveraged to monitor and trend prescribing patterns to identify opportunities for therapeutic interventions, forecast upcoming usage for better inventory management, and implement cost-avoidance strategies.

Medications purchased specifically for the management of patients with COVID-19 can also be tracked to generate real-time budget variance reports for financial stakeholders and the hospital leadership to maintain fiscal awareness.

Staff education and team management. Department of pharmacy personnel are essential for safe, effective, and timely pharmaceutical care during the COVID-19 pandemic.

Thus, it is key to provide knowledge and resources necessary for staff safety and protection during performance of patient care duties. Staff education regarding institutional procedures should be implemented as soon as possible; this includes educating personnel about proper hand hygiene and other infection control strategies, social distancing recommendations, removal and disposal of PPE, and hospital-approved PPE conservation measures, as well as outlining scenarios that require specific types of PPE. The staff should be provided with official procedures developed by the institution's human resources department, employee health services personnel, and/or the department of health regarding asymptomatic and symptomatic employees, potential exposure, testing availability, and return-to-work procedures.

In lieu of in-person meetings, conference calls and virtual huddles may become the preferred method of disseminating information and clinical updates in a timely fashion.

Pharmacy department leaders can consider scheduling these sessions at routine intervals so that staff members can plan appropriately, with additional ad hoc meetings held as needed.

Huddles may need to be repeated or recorded to ensure that all shifts and departmental areas are included. The choice of communication platform may vary with the institution's or department's subscription offerings. The use of secure messaging software can be optimized to promote team communication and smooth patient handoffs for optimal care coordination and continuity. Prior to implementation of new communication platforms, the department of pharmacy should assess whether software programs are compliant with Health Insurance Portability and Accountability Act (HIPAA) privacy and confidentiality requirements.

In light of the highly contagious nature of SARS-CoV-2, remote work by eligible pharmacy staff can be explored as a way to reduce the risk of virus exposure. Pharmacists can remotely participate in medication order verification, deliver many of the aforementioned clinical pharmacy services, partake in table rounds to discuss admitted patients, and provide pharmacy informatics support. Administrators, administrative assistants, compliance and regulatory specialists, and members of supply chain teams and teams responsible for managing 340B Drug Pricing Program participation who are not physically involved in distribution may also be considered. Rotation schedules for remote work should be discussed and agreed upon in advance and readily available for staff to reference in case an individual must be contacted. With the call to reduce in-person interactions, there has been an invigorated interest in expansion of telehealth and telemedicine services. Ambulatory care and transitions of care pharmacists can identify patients discharged after treatment for COVID-19 who are at high risk for readmission (or receive referrals directly from partnering providers) and establish pharmacist-patient telehealth appointments. Pharmacotherapy assessments, patient counseling and education, medication therapy management, and collaborative drug therapy management (if applicable) can be performed via telehealth. New treatments may have been initiated during an admission for COVID-19, and a postdischarge telehealth visit will allow pharmacists to also follow up to ensure appropriate duration of therapy and detection of adverse effects. Many telehealth platforms are already compliant with HIPAA requirements, and the HHS Office for Civil Rights has issued a notification of enforcement discretion regarding provision of telehealth services using noncompliant platforms during the public health emergency. 29 Pharmacists participating in the aforementioned telehealth services should determine proper billing and reimbursement procedures as necessary.

Sciences University, receiving the COVID-19-only designation meant having to quickly prepare the institution and Department of Pharmacy for the incoming case surge while also being able to exercise change management skills to adapt to the evolving situation, which came with its unique challenges. One of the most prominent issues was the national shortage of PPE supplies, specifically those used by clinical pharmacists in critical care areas, operational pharmacists in sterile and hazardous product compounding, and pharmacy technicians performing ADC restocking and crash cart exchanges. By proactively projecting daily and weekly numbers for expected staff PPE usage, we were able to communicate frequently with our central sterile supply distribution team for allocation purposes. These estimates were based on in-person staffing schedules and shifts; the expected numbers of trips needed for medication restocking, crash cart exchanges, and emergency responses; and guidance from the institution regarding PPE conservation strategies. We also collaborated with clinicians to modify standard medication administration times for various drugs to minimize nursing staff virus exposure and to preserve PPE supplies.

Given the expansion of intensive care unit capacity and unit bed counts, our pharmacists with expertise in critical care medicine were contacted frequently by providers, nurses, and fellow pharmacists without formal training in critical care medicine. A major challenge was being able to field and triage these patient-specific requests in a timely manner. Thus, we created guidelines for use of common critical care medications, including guidance on dose titration of continuous-infusion medications (ie, vasopressors, sedatives, opioids, neuromuscular blocking agents) and anticoagulation therapy in critically ill patients in the setting of COVID-19. Intensive care areas were impacted the most by critical drug shortages.

Clinical pharmacists assisted with quickly transitioning our most frequently used sedative, opioid, and neuromuscular blocker infusions to less frequently used or rarely used alternatives while optimizing the use of adjunctive pharmacotherapies for pain, agitation, and sedation. This process involved significant provider, nurse, and pharmacist education and work by our pharmacy informaticists to ensure that drug information in the EMR for these agents was updated and relevant.

The operational pharmacy workflow changed considerably, with significant increases in labor-intensive tasks such as sterile compounding, restocking of ADCs, and exchanging of crash carts and emergency kits. The scenario was complicated by the absence of numerous staff on sick leave for mandatory self-quarantines due to SARS-CoV-2 exposure. Several mitigation strategies were immediately enacted. First, with the closing of various outpatient clinics, ambulatory surgery centers, and infusion suites, staff were redeployed to the inpatient pharmacy or reassigned to clinical COVID-19 teams. Second, operational pharmacists agreed to step into pharmacy technician roles as needed during technician staffing shortages. Third, clinical pharmacists assumed a significant portion of order verification responsibilities through reassignment to decentralized services or remote work, allowing operational staff more time to attend to labor-intensive tasks. Finally, we coordinated with our human resources colleagues and the credentialing office to fast-track and onboard volunteers, who proved to be of great assistance during the peak of the pandemic.

Summary. The COVID-19 pandemic presents numerous challenges for hospitals and departments to maintain operations necessary for patient care delivery. Comprehensive pharmacy and medication management services are still needed to promote safe and costeffective drug utilization during the public health crisis. Areas of focus include provision of operational services, clinical services, drug shortage strategies, informatics support, and team management. Opportunities for expansion of services during the pandemic include pharmacistinitiated point-of-care testing and telehealth services. Although it may be difficult to predict the exact time and extent of a COVID-19 surge in different areas of the United States, departments of pharmacy may implement preparedness plans and best practices in conjunction with providers, hospital leaderships, and other departments to serve the needs of their patients and healthcare colleagues.

Defining pharmacists' roles in disasters: a Delphi study

Lessons learned from Hurricane Maria: pharmacists' perspective

Hurricane Harvey and pharmacy's call to action

Pharmacists' roles in post-September 11 th disasters: a content analysis of pharmacy literature

New Jersey hospitals come through during Hurricane Sandy

The nontraditional roles of pharmacists after Hurricane Katrina: process description and lessons learned

A PHS pharmacist team's response to Hurricane Katrina

Pharmacist readiness roles for emergency preparedness

Pharmacy leader's role in hospital emergency preparedness planning

Defining roles for pharmacy personnel in disaster response and emergency preparedness

Effects of a new sterile product preparation and delivery process on operational efficiency and cost

Impact of sterile compounding batch frequency on pharmaceutical waste

General chapter <797> pharmaceutical compounding -sterile preparations

Method to determine allocation of clinical pharmacist resources

Impact on patient outcomes of pharmacist participation in multidisciplinary critical care teams: a systematic review and meta-analysis

Clinical pharmacy services in the emergency department

Evaluation of pharmacy resident perceived impact of natural disaster on stress during pharmacy residency training

Development and validation of a medication regimen complexity scoring tool for critically ill patients

Characterization of changes in medication complexity using a modified scoring tool

Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review

Ensuring access to medications in the US during the COVID-19 pandemic

Drug shortages: a complex health care crisis

ASHP guidelines on managing drug product shortages

ASHP statement of pharmacist's role in clinical informatics

Factors associated with barcode medication administration technology that contribute to patient safety: an integrative review

Pharmacy dashboard: an innovative process for pharmacy workload and productivity

Development of health-system inpatient pharmacy clinical metrics

Office of the Assistant Secretary for Health, US Department of Health and Human Services. Guidance for licensed pharmacists, COVID-19 testing, and immunity under the PREP act

Office for Civil Rights, US Department of Health and Human Services. Notification of enforcement discretion for telehealth remote communications during the COVID-19 nationwide public health emergency